A

Acura Pharmaceuticals Inc
OTC:ACUR

Watchlist Manager
Acura Pharmaceuticals Inc
OTC:ACUR
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: 33.2k USD

Acura Pharmaceuticals Inc
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acura Pharmaceuticals Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
A
Acura Pharmaceuticals Inc
OTC:ACUR
Operating Expenses
-$2.8m
CAGR 3-Years
14%
CAGR 5-Years
23%
CAGR 10-Years
12%
Johnson & Johnson
NYSE:JNJ
Operating Expenses
-$37.9B
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Expenses
-$19B
CAGR 3-Years
9%
CAGR 5-Years
3%
CAGR 10-Years
-7%
Pfizer Inc
NYSE:PFE
Operating Expenses
-$28.8B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Operating Expenses
-$26.1B
CAGR 3-Years
-6%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Eli Lilly and Co
NYSE:LLY
Operating Expenses
-$22.9B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-8%
No Stocks Found

Acura Pharmaceuticals Inc
Glance View

Market Cap
32.5k USD
Industry
Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. The firm has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The firm's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The firm's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The firm's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.

ACUR Intrinsic Value
Not Available
A

See Also

What is Acura Pharmaceuticals Inc's Operating Expenses?
Operating Expenses
-2.8m USD

Based on the financial report for Dec 31, 2021, Acura Pharmaceuticals Inc's Operating Expenses amounts to -2.8m USD.

What is Acura Pharmaceuticals Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
12%

Over the last year, the Operating Expenses growth was 36%. The average annual Operating Expenses growth rates for Acura Pharmaceuticals Inc have been 14% over the past three years , 23% over the past five years , and 12% over the past ten years .

Back to Top